RT Journal Article
SR Electronic
T1 Trends in risk factors and symptoms associated with SARS-CoV-2 and Rhinovirus test positivity in King County, Washington: A Test-Negative Design Study of the Greater Seattle Coronavirus Assessment Network
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.12.22278203
DO 10.1101/2022.08.12.22278203
A1 Hansen, Chelsea L.
A1 Perofsky, Amanda
A1 Burstein, Roy
A1 Famulare, Michael
A1 Boyle, Shanda
A1 Prentice, Robin
A1 Marshall, Cooper
A1 McCormick, Benjamin JJ
A1 Reinhart, David
A1 Capodanno, Ben
A1 Truong, Melissa
A1 Schwabe-Fry, Kristen
A1 Kuchta, Kayla
A1 Pfau, Brian
A1 Acker, Zack
A1 Lee, Jover
A1 Sibley, Thomas R.
A1 McDermot, Evan
A1 Rodriguez-Salas, Leslie
A1 Stone, Jeremy
A1 Gamboa, Luis
A1 Han, Peter D.
A1 Duchin, Jeffery S.
A1 Waghmare, Alpana
A1 Englund, Janet A.
A1 Shendure, Jay
A1 Bedford, Trevor
A1 Chu, Helen Y.
A1 Starita, Lea M.
A1 Viboud, Cécile
YR 2022
UL http://medrxiv.org/content/early/2022/08/18/2022.08.12.22278203.abstract
AB Importance Few US studies have reexamined risk factors for SARS-CoV-2 positivity in the context of widespread vaccination and new variants or considered risk factors for co-circulating endemic viruses, such as rhinovirus.Objective To understand how risk factors and symptoms associated with SARS-CoV-2 test positivity changed over the course of the pandemic and to compare these to the factors associated with rhinovirus test positivity.Design This test-negative design study used multivariable logistic regression to assess associations between SARS-CoV-2 and rhinovirus test positivity and self-reported demographic and symptom variables over a 22-month period.Setting King County, Washington, June 2020-April 2022Participants 23,278 symptomatic individuals of all ages enrolled in a cross-sectional community surveillance study.Exposures Self-reported data for 15 demographic and health behavior variables and 16 symptoms.Main Outcome(s) and Measure(s) RT-PCR confirmed SARS-CoV-2 or rhinovirus infection.Results Close contact with a SARS-CoV-2 case (adjusted odds ratio, aOR 4.3, 95% CI 3.7-5.0) and loss of smell/taste (aOR 3.7, 95% CI 3.0-4.5) were the variables most associated with SARS-CoV-2 test positivity, but both attenuated during the Omicron period. Contact with a vaccinated case (aOR 2.4, 95% CI 1.7-3.3) was associated with a lower odds of test positivity than contact with an unvaccinated case (aOR 4.4, 95% CI 2.7-7.3). Sore throat was associated with Omicron infection (aOR 2.3, 95% CI 1.6-3.2) but not Delta. Vaccine effectiveness for participants fully vaccinated with a booster dose was 43% (95% CI 11-63%) for Omicron and 92% (95% CI 61-100%) for Delta.Variables associated with rhinovirus test positivity included age <12 years (aOR 4.0, 95% CI 3.5-4.6) and reporting a runny or stuffy nose (aOR 4.6, 95% CI 4.1-5.2). Race, region, and household crowding were significantly associated with both SARS-CoV-2 and rhinovirus test positivity.Conclusions and Relevance Estimated risk factors and symptoms associated with SARS-CoV-2 infection have changed over time. There was a shift in reported symptoms between the Delta and Omicron variants as well as reductions in the protection provided by vaccines. Racial and socioeconomic disparities persisted in the third year of SARS-CoV-2 circulation and were also present in rhinovirus infection, although the causal pathways remain unclear. Trends in testing behavior and availability may influence these results.Question What are the characteristics associated with SARS-CoV-2 and rhinovirus infection?Findings In this test-negative design study of 23,278 participants, reporting close contact with a SARS-CoV-2 case was the strongest risk factor associated with test positivity. Loss of smell and taste was associated with the Delta variant, but not the Omicron variant. Vaccination and prior infection provided greater protection against Delta infection than Omicron Infection. Young age was the strongest predictor of rhinovirus positivity. Sociodemographic disparities were present for both SARS-CoV-2 and rhinovirus.Meaning Monitoring factors associated with respiratory pathogen test positivity remains important to identify at-risk populations in the post-SARS-CoV-2 pandemic period.Competing Interest StatementCLH received contract-based fees from Sanofi Pasteur outside of the submitted work. AW reported grant support from Ansun Biopharma, Allovir, and Pfizer, and serves as an Advisory Board Member for Kyorin Pharmaceutical. JAE reported research support from AstraZeneca, GlaxoSmithKline, Merck, and Pfizer, and is a consultant for Sanofi Pasteur, Meissa Vaccines, AstraZeneca, and Moderna. HYC reported consulting with Ellume, Abbvie, Pfizer, The Bill and Melinda Gates Foundation, Vindico CME, and Merck. HYC received research funding from Gates Ventures, Sanofi Pasteur, and support and reagents from Ellume and Cepheid outside of the submitted work. All other authors declare no conflicts of interest.Funding StatementThis study was funded by Gates Ventures. RB and MF are employees of the Institute for Disease Modeling, a research group within, and solely funded by, the Bill and Melinda Gates Foundation. JS and TB are supported by the Howard Hughes Medical Institute Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Washington gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors